International Survey Finds Self-Administered Treatment on the Rise Among Hereditary Angioedema Patients

   International Survey Finds Self-Administered Treatment on the Rise Among
                        Hereditary Angioedema Patients

Responding HAE specialists agree that self-administration is advantageous to
patients' time, independence and convenience

PR Newswire

BALTIMORE, Nov. 8, 2013

BALTIMORE, Nov. 8, 2013 /PRNewswire/ --More patients with hereditary
angioedema (HAE), a rare and potentially fatal genetic disorder, are being
offered and opting for self-administration therapy, according to data from a
new survey being presented at the 2013 American College of Allergy, Asthma &
Immunology (ACAAI) Annual Meeting. Of the HAE treatment centers surveyed in
Europe, Canada and the United States, the majority (70 percent) reported that
at least 50 percent of patients were now self-administering their therapy, and
the HAE specialists who responded agreed that this treatment option is
advantageous to patients, citing key benefits as time saved, independence and

"HAE attacks can be serious, painful and frightening, and until recently they
required most patients to travel to a clinic or emergency department for
treatment, a time-consuming process that can increase the patient's anxiety,"
said Timothy J. Craig, D.O., Professor of Medicine and Pediatrics at Penn
State University in Hershey, Pennsylvania, and one of the study's
investigators."Fortunately, three HAE therapies are now indicated for
self-administration, which our survey confirmed has the potential to minimize
the burden of disease for these patients because when faced with an attack,
they can intervene earlier."

According to results of the 16-question, online survey, physicians agreed that
all patients should be considered for self treatment if certain
characteristics are met, including motivation, mental ability and clinical
need. While all HAE centers included in the survey offer self-administration,
centers in Europe and Canada provide self-administration training. Centers in
the United States offer training through a home-nursing agency. Survey
respondents also agreed that barriers to self-administration still exist,
specifically citing a patient's infusion skill set. Instituting a 24-hour
hotline was one solution offered by physicians as way to overcome this

The survey was sponsored by CSL Behring, which markets Berinert^® (C1
inhibitor [C1-INH]), one of the three HAE therapies currently indicated for

About Berinert®
Berinert, C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered,
plasma-derived intravenous therapy, treats acute attacks of facial, abdominal
and laryngeal hereditary angioedema (HAE) symptoms by providing C1 Esterase
Inhibitor deficient adult and adolescent patients with the missing human
protein. The safety and efficacy of Berinert in preventing HAE attacks have
not been established.

Without C1 Esterase Inhibitor, people with HAE suffer from recurrent episodes
of rapid swelling of areas of the skin and underlying tissues, including the
face, mouth, throat and abdomen. CSL Behring has marketed its pasteurized and
nanofiltered C1 Esterase Inhibitor concentrate, Berinert, in Germany for more
than 30 years. The product is also approved and marketed in 23 other European
countries, the United States, Australia, Canada, Israel, Argentina, Japan and
South Korea.

Berinert is contraindicated in individuals with a history of life-threatening
systemic reactions to C1 Esterase Inhibitor preparations, including
anaphylaxis. The most serious adverse reaction reported in subjects who
received Berinert in clinical studies was an increase in the severity of pain
associated with HAE. In placebo-controlled clinical trial, dysgeusia was the
most common adverse reaction reported in over 4 percent of subjects who
received Berinert and more frequently than in the placebo group. Thrombotic
events have been reported in patients receiving C1 Esterase Inhibitor product,
including Berinert, at the recommended dose as well as when used off-label or
at higher-than-labeled doses.

Berinert is derived from human plasma. The risk of transmission of infectious
agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease
(CJD) agent, cannot be completely eliminated. Please see full prescribing
information for Berinert.

About HAE
HAE is a genetic disorder caused by a deficiency of C1-INH and is inherited in
an autosomal dominant manner. Symptoms of HAE include episodes of edema or
swelling in the face, abdomen, larynx and extremities. Patients who have
abdominal attacks of HAE can experience episodes of severe pain, diarrhea,
nausea and vomiting caused by swelling of the intestinal wall. HAE attacks
that involve the face can cause painful distortion and painful swelling.
Diagnosis of HAE requires a blood test to confirm low or abnormal levels of

About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry.
Passionate about improving the quality of patients' lives, CSL Behring
manufactures and markets a range of safe and effective plasma-derived and
recombinant products and related services. The company's therapies are used in
the treatment of immune deficiency disorders, hereditary angioedema,
hemophilia, von Willebrand disease, other bleeding disorders and inherited
emphysema. Other products are used for the prevention of hemolytic diseases in
the newborn, in cardiac surgery, organ transplantation and in the treatment of
burns. The company also operates one of the world's largest plasma collection
networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a
biopharmaceutical company with headquarters in Melbourne, Australia. For more
information, visit

Sheila A. Burke
Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
O: 610-878-4209


Press spacebar to pause and continue. Press esc to stop.